Q-omics provides the consensus-scored ELANE profile across patient tissues and cancer cell-line models. ELANE expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ELANE is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, ELANE protein abundance shows 26,650 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, COAD, and LUAD as cancer lineages where ELANE shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELANE — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELANE survival associations across molecular data types. ELANE RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELANE RNA expression–survival associations across cancer types. High ELANE expression shows unfavorable associations in KIRC and LUSC, but favorable associations in HNSC, LAML, SARC and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ELANE RNA expression.
This table summarizes ELANE tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ELANE. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELANE shows lower tumor expression in COAD, BLCA, LUSC, HNSC, READ and STAD. The COAD box plot shows higher ELANE RNA expression in normal versus tumor tissue (log2 FC = −1.346, t-test p < 0.001).
This table shows molecular features associated with ELANE in patient tissues and cancer cell lines. In patient samples, ELANE shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ELANE RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
